Lepu Biopharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	934.87	367.79	225.35	15.57	-
Revenue Growth (YoY)	154.18%	63.21%	1347.16%	-	-
Cost of Revenue	89.59	74.82	28.28	2.01	-
Gross Profit	845.28	292.97	197.08	13.57	-
Selling, General & Admin	354.46	237.89	129.95	140.58	156.24
Research & Development	400.71	437.7	458.07	524.29	791.21
Other Operating Expenses	-195.02	13.23	-0.38	-8.85	-3.77
Operating Expenses	560.15	688.82	587.65	656.02	943.68
Operating Income	285.13	-395.85	-390.57	-642.45	-943.68
Interest Expense	-29.31	-21.65	-14.68	-7.47	-2.7
Interest & Investment Income	-	4.67	8.18	8.35	9.1
Earnings From Equity Investments	-7.51	-16.44	-27.34	-32.23	-17.7
Currency Exchange Gain (Loss)	-	1.33	0.21	37.75	-2.41
Other Non Operating Income (Expenses)	12.33	3.74	173.64	-64	-76.86
EBT Excluding Unusual Items	260.64	-424.2	-250.56	-700.05	-1,034
Gain (Loss) on Sale of Investments	-	-	220.26	-	5.37
Gain (Loss) on Sale of Assets	-	0.01	-	0.61	-
Pretax Income	260.64	-424.19	-30.3	-699.44	-1,029
Income Tax Expense	1.75	-	-	-	-
Earnings From Continuing Operations	258.89	-424.19	-30.3	-699.44	-1,029
Minority Interest in Earnings	2.48	12.82	8.21	10.39	17.87
Net Income	261.36	-411.38	-22.1	-689.05	-1,011
Net Income to Common	261.36	-411.38	-22.1	-689.05	-1,011
Shares Outstanding (Basic)	1,742	1,690	1,659	1,641	1,520
Shares Outstanding (Diluted)	1,742	1,690	1,659	1,641	1,520
Shares Change (YoY)	3.07%	1.87%	1.14%	7.92%	33.97%
EPS (Basic)	0.15	-0.24	-0.01	-0.42	-0.66
EPS (Diluted)	0.15	-0.24	-0.01	-0.42	-0.66
Free Cash Flow	-	-229.31	-278.84	-591.38	-835.12
Free Cash Flow Per Share	-	-0.14	-0.17	-0.36	-0.55
Gross Margin	90.42%	79.66%	87.45%	87.12%	-
Operating Margin	30.50%	-107.63%	-173.32%	-4125.67%	-
Profit Margin	27.96%	-111.85%	-9.80%	-4424.94%	-
Free Cash Flow Margin	-	-62.35%	-123.73%	-3797.71%	-
EBITDA	367.29	-313.69	-306.66	-564.63	-866.49
EBITDA Margin	39.29%	-85.29%	-136.08%	-	-
D&A For EBITDA	82.16	82.16	83.91	77.82	77.18
EBIT	285.13	-395.85	-390.57	-642.45	-943.68
EBIT Margin	30.50%	-107.63%	-173.31%	-	-
Effective Tax Rate	0.67%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.